A HEALTHCARE manufacturer has announced it is set to expand operations into Reading after securing government funding.
Lonza, a global manufacturer of healthcare products including bio-pharmaceuticals, drug synthesis, and gene therapies, has received funding from the UK government with a view to expanding its biologistics operations.
Now the firm has confirmed it will begin developing a plot in Thames Valley Science Park, fostering further growth for the company.
It will also support the continued development and manufacture of bio-pharmaceuticals in the UK.
Science minister Lord Patrick Vallance said that Lonza had “exciting ambitions” which would support government plans to “build an NHS fit for the future.”
Head of the Mammalian Business Unit, Biologics at Lonza, Stefan Egli, said: “We are grateful to the UK Government for its support as we seek to relocate and expand our UK footprint and capability.
“Our Biologics site in Slough and its highly-skilled workforce, now comprising more than 1,000 people, has been an integral part of our global business for more than 25 years.
“During this time, the site has supported both large pharma and small biotech customers in bringing innovative therapies to life for their patients.
“We are pleased to have secured a desirable plot in Thames Valley Park with the opportunity to grow and strengthen Lonza’s operations in the UK, which is a strategically important market for our business.”
More information about Lonza is available via: lonza.com
